Ecnoglutide Phase 3 trial (NCT05680155)
A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone
Registry record checked
At a glance
- Phase
- Phase 3
- Status
- Completed
- Enrolment
- 211
- actual
- Start
- 29 Dec 2022 (actual)
- Primary completion
- 12 Jun 2024 (actual)
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| C1-XW003 | Experimental | Drug: Ecnoglutide | High dosage of XW003 once weekly |
| C1-Placebo | Placebo comparator | Drug: Placebo | Matched Placebo once weekly |
| C2-XW003 | Experimental | Drug: Ecnoglutide | Low dosage of XW003 once weekly |
| C2-Placebo | Placebo comparator | Drug: Placebo | Matched Placebo once weekly |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Change from baseline in HbA1c | Baseline, Week 24 |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Change from baseline in HbA1c | Baseline, Week 5, Week 9, Week 13, Week 17, Week 29, Week 33, Week 37, Week 45, Week 52 |
| Proportion of subjects with HbA1c < 7% and HbA1c ≤6.5% after treatment | week 24, week 52 |
| Proportion of subjects with HbA1c < 7%, with no severe hypoglycemia or no weight gain | week 24 |
| Change from baseline in fasting plasma glucose (FPG) | Baseline, Week 24 and Week 52 |
| Change from baseline in fasting insulin | Baseline, Week 24 and Week 52 |
| Change from baseline in lipid panel | Baseline, Week 24 and Week 52 |
| Change from baseline in 2-hour postprandial blood glucose | Baseline, Week 24 and Week 52 |
| Change from baseline in 7-point self-monitored blood glucose | Baseline, Week 24 and Week 52 |
| Change from baseline in HOMA-IR | Baseline, Week 24 and Week 52 |
| Change from baseline in HOMA-β | Baseline, Week 24 and Week 52 |
| Change from baseline in body weight | Baseline, Week 24 and Week 52 |
| Change from baseline in waist circumference | Baseline, Week 24 and Week 52 |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Patients With T2DM Inadequately Controlled by Diet and Exercise AloneClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.